Conformal Risk Prediction for Non-Alcoholic Fatty Liver Disease Using Gradient Boosting with Distribution-Free Coverages

Structured tabular data dominates clinical medicine, yet existing benchmarks fail to reflect real-world properties like complex survey sampling, demographic oversampling, and subgroup fairness. We introduce the NHANES Accelerometry Cardiometabolic Benchmark, derived from NHANES 2003-2006, comprising 1,381 adults with hip-worn accelerometry, fasting laboratory biomarkers, dietary intake, and anthropometrics. We evaluate three tabular learning methods -- ridge regression, XGBoost, and the foundation model TabPFN v2 -- to predict glycated haemoglobin (HbA1c), fasting triglycerides, and C-reactive protein (CRP) from activity phenotypes and lifestyle covariates. TabPFN v2 achieves the best overall performance (HbA1c R^2=0.156, CRP R^2=0.383), while triglycerides remain largely unpredictable (R^2 < 0.05), consistent with known genetic dominance. We apply split conformal prediction to generate distribution-free 90% prediction intervals and evaluate demographic coverage equity across sex and race/ethnicity subgroups. Marginal coverage aligns with the 90% target for CRP and HbA1c but falls below for triglycerides. At the subgroup level, we observe localized undercoverage (e.g., HbA1c for Mexican American participants), illustrating the gap between marginal guarantees and the conditional coverage required for clinical fairness. Code and data are at https://github.com/felizzi/nhanes-accel-cardiometabolic-benchmark.

Dysglycemia, encompassing both prediabetes and diabetes, affects huge numbers of adults worldwide, yet many of them remain undiagnosed. We developed and validated machine-learning (ML) models for non-invasive screening of dysglycemia risk that require no laboratory tests. Pooling data from the National Health and Nutrition Examination Survey (NHANES) 2017--2023 (n=14,352), we trained six ML models with stratified 5-fold cross-validation and compared them with two established clinical risk scores. LightGBM achieved the highest area under the receiver operating characteristic curve (AUC=0.820, 95% CI: 0.806--0.835), outperforming the Finnish Diabetes Risk Score (0.745) and American Diabetes Association Risk Test (0.783). SHAP analysis identified age, race/ethnicity, and waist-to-height ratio as the most influential predictors. Subgroup analyses confirmed consistent performance across demographic strata (AUC: 0.735--0.832). These results demonstrate the feasibility of explainable, laboratory-free dysglycemia screening for deployment in community settings and self-tracking health applications.

Advanced fibrosis is a major determinant of liver-related morbidity in metabolic dysfunction-associated steatotic liver disease (MASLD). FIB-4 is widely used as a first-line non-invasive test, but its fixed formula may underuse diagnostic information contained in age, aspartate aminotransferase, alanine aminotransferase, and platelet count. We evaluated whether machine-learning-enhanced non-invasive testing (MLE-NIT) can improve advanced fibrosis detection while preserving this FIB-4 variable space. We used three biopsy-confirmed MASLD cohorts from China, Malaysia, and India (n=784). The Chinese cohort was split into 486 training and 54 internal validation/tuning patients; final performance was reported only on the Malaysian and Indian external cohorts. Models used five variables: age, FIB-4, aspartate aminotransferase, platelet count, and alanine aminotransferase. We compared FIB-4 with a shallow-deep neural network (s-DNN), TabPFN, and gpt-4o-2024-08-06. FIB-4 achieved external ROC-AUCs of 0.75 and 0.60 in Malaysia and India, respectively. TabPFN achieved 0.69 and 0.66, fine-tuned GPT-4o achieved 0.75 and 0.63, and the s-DNN achieved 0.77 and 0.67, respectively. The s-DNN contained only 354 trainable parameters, compared with 7,244,554 for TabPFN, yet provided a more balanced external operating profile. Calibration showed s-DNN Brier scores of 0.18 and 0.22, and permutation importance identified AST and FIB-4 as dominant variables. Compact non-linear MLE-NITs may enhance FIB-4-based fibrosis assessment without increasing clinical data requirements.